Related Experiment Video
Updated: Mar 28, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
The effect of 25-hydroxyvitamin D levels on QT interval duration and dispersion in type 2 diabetic patients
Demet Ozgil Yetkin1, Belgin Kucukkaya, Mehtap Turhan
1Demet Ozgil Yetkin, Ortaklar Caddesi, Kosem Apt. no: 10/8, Mecidiyekoy, Istanbul, Turkey, demetozgil@yahoo.com.
Aim:
To assess the relationship between corrected QT (QTc) interval and vitamin 25-hydroxyvitamin D levels (25-OHD) deficiency in type 2 diabetic patients.
Methods:
The study included 253 patients with type 2 diabetes and 170 age-matched controls treated between October and December 2013. QTc duration and QTc dispersion were measured on ECG recordings and 25-OHD, calcium, phosphorus, and blood glucose levels were determined.
Results:
Patients with diabetes had significantly longer QTc duration and QTc dispersion than controls (P<0.001 and P<0.001 respectively). Diabetic patients with prolonged QTc duration were older and had longer diabetes duration and higher HbA1c levels than patients with normal QTc interval. They significantly more frequently had 25-OHD deficiency (P<0.001), but had similar calcium and phosphorus levels. Diabetic patients with prolonged QTc dispersion were of similar age and had similar diabetes duration and HbA1c levels as patients with normal QTc dispersion. They significantly more frequently had 25-OHD deficiency (P=0.010), but had similar calcium and phosphorus levels.
Conclusion:
This study showed prolonged QTc duration and QTc dispersion in patients with type 2 diabetes, especially those with 25-OHD deficiency.
More Related Videos
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Therapeutic Drug Monitoring: Affecting Factors
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Antihypertensive Drugs: Thiazide-Class Diuretics
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

